| pubmed-article:9815590 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C0138741 | lld:lifeskim |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C1704256 | lld:lifeskim |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C0022265 | lld:lifeskim |
| pubmed-article:9815590 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9815590 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:9815590 | pubmed:dateCreated | 1999-2-25 | lld:pubmed |
| pubmed-article:9815590 | pubmed:abstractText | The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-alpha administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-alpha was assessed by the measurement of plasma TGF-beta1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-beta1 levels increased with CRA and IFN-alpha therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF-beta1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-alpha can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-beta1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored. | lld:pubmed |
| pubmed-article:9815590 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9815590 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9815590 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9815590 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9815590 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:ThompsonSS | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:GalliPP | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:CummingsK BKB | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:AisnerJJ | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:WeissR ERE | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:JirtleR LRL | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:RasheedZZ | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:AnscherMM | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:TsaiH KHK | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:GoodinSS | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:KongF MFM | lld:pubmed |
| pubmed-article:9815590 | pubmed:author | pubmed-author:DiPaolaR SRS | lld:pubmed |
| pubmed-article:9815590 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9815590 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:9815590 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9815590 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9815590 | pubmed:pagination | 1999-2004 | lld:pubmed |
| pubmed-article:9815590 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:meshHeading | pubmed-meshheading:9815590-... | lld:pubmed |
| pubmed-article:9815590 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9815590 | pubmed:articleTitle | Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. | lld:pubmed |
| pubmed-article:9815590 | pubmed:affiliation | Departments of Medicine and Surgery, Division of Urology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA. | lld:pubmed |
| pubmed-article:9815590 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9815590 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9815590 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9815590 | pubmed:publicationType | Multicenter Study | lld:pubmed |
